Biosimilars: What’s in a Name? – Pharmaceutical Commerce Magazine
Precision for Value’s Jeremy Schafer is quoted in an article that discusses the naming of biosimilars. He concludes that the payer community will find a way to track biosimilar sourcing, usage and reimbursement regardless of naming conventions or HCPCS codes.
Q&A: Regulatory Expert Karen Becker Provides Context for Theranos, FDA Interactions – GenomeWeb
Karen M. Becker, PhD, Managing Director, Translational and Regulatory Sciences at Precision for Medicine, provides expertise for the diagnostics industry in navigating the complexities of the Food and Drug Administration.
Precision for Medicine acquires Redwood Outcomes, a Canadian HEOR firm – Pharmaceutical Commerce Magazine
Precision for Value, a unit of New York-based Precision for Medicine, is adding Redwood Outcomes, based in Vancouver, BC to its stable.
Commentary: Biosimilars – Why Deep Discounts May Become the Dominant Paradigm
Precision for Value’s Jeremy Schafer, Michael Tapella, and Thanos Kantarelis conclude that discounts in the biosimilar market may be significantly deeper than originally expected.
Precision for Value Acquires Redwood Outcomes – NJBIZ
Dan Renick is quoted in NJBIZ on Precision’s Redwood Outcomes HEOR acquisition.